Gilead Sciences, Inc. (GILD) Cut to Neutral at Citigroup Inc.

Citigroup Inc. downgraded shares of Gilead Sciences, Inc. (NASDAQ:GILD) from a buy rating to a neutral rating in a report published on Wednesday morning. Citigroup Inc. currently has $76.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $87.00.

A number of other brokerages have also recently commented on GILD. Credit Suisse Group reduced their target price on shares of Gilead Sciences from $93.00 to $79.00 and set an outperform rating for the company in a research report on Wednesday, February 8th. RBC Capital Markets reduced their target price on shares of Gilead Sciences from $95.00 to $90.00 and set an outperform rating for the company in a research report on Wednesday, November 2nd. Vetr cut shares of Gilead Sciences from a strong-buy rating to a buy rating and set a $84.73 target price for the company. in a research report on Wednesday, January 4th. Piper Jaffray Companies reiterated an overweight rating on shares of Gilead Sciences in a research report on Saturday, October 22nd. Finally, Jefferies Group LLC reiterated a buy rating on shares of Gilead Sciences in a research report on Tuesday, November 8th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $88.94.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) opened at 67.65 on Wednesday. The stock’s 50 day moving average is $72.08 and its 200 day moving average is $75.53. Gilead Sciences has a 52 week low of $65.38 and a 52 week high of $103.10. The stock has a market cap of $88.62 billion, a PE ratio of 6.81 and a beta of 1.11.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 7th. The biopharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.61 by $0.09. The business had revenue of $7.30 billion for the quarter, compared to the consensus estimate of $7.16 billion. Gilead Sciences had a net margin of 44.43% and a return on equity of 92.36%. The company’s revenue was down 13.9% compared to the same quarter last year. During the same period last year, the firm posted $3.32 earnings per share. Analysts predict that Gilead Sciences will post $8.88 EPS for the current year.

This article was reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be viewed at http://sleekmoney.com/gilead-sciences-inc-gild-cut-to-neutral-at-citigroup-inc/1659332.html.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 30th. Shareholders of record on Thursday, March 16th will be paid a $0.52 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.47. This represents a $2.08 annualized dividend and a yield of 3.07%. The ex-dividend date of this dividend is Tuesday, March 14th. Gilead Sciences’s payout ratio is currently 18.91%.

In other Gilead Sciences news, insider John C. Martin sold 73,337 shares of the business’s stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $73.59, for a total transaction of $5,396,869.83. Following the sale, the insider now directly owns 3,204,433 shares in the company, valued at approximately $235,814,224.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John W. Madigan sold 105,000 shares of the business’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the sale, the director now owns 121,761 shares in the company, valued at $9,115,028.46. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Several large investors have recently modified their holdings of GILD. Tarbox Group Inc. raised its stake in shares of Gilead Sciences by 0.4% in the third quarter. Tarbox Group Inc. now owns 6,522 shares of the biopharmaceutical company’s stock valued at $516,000 after buying an additional 27 shares during the last quarter. West Oak Capital LLC raised its stake in shares of Gilead Sciences by 0.7% in the third quarter. West Oak Capital LLC now owns 4,449 shares of the biopharmaceutical company’s stock valued at $352,000 after buying an additional 32 shares during the last quarter. Alpha Windward LLC raised its stake in shares of Gilead Sciences by 1.0% in the third quarter. Alpha Windward LLC now owns 3,410 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 33 shares during the last quarter. Sullivan Bruyette Speros & Blaney LLC raised its stake in shares of Gilead Sciences by 0.6% in the fourth quarter. Sullivan Bruyette Speros & Blaney LLC now owns 6,779 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 42 shares during the last quarter. Finally, Albion Financial Group UT raised its stake in shares of Gilead Sciences by 0.6% in the third quarter. Albion Financial Group UT now owns 6,771 shares of the biopharmaceutical company’s stock valued at $536,000 after buying an additional 43 shares during the last quarter. Institutional investors own 74.19% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/gilead-sciences-inc-gild-cut-to-neutral-at-citigroup-inc/1659332.html

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *